Similarly, Y372C missense gain-of-function mutation in FGFR1 in osteoglophonic dysplasia (OGD) and systemic administration of activating antibodies to FGFR1 in mice elevate circulating FGF23 levels [79], but have the confounding effects of activation of FGFRs in both bone and kidney. This evidence concerns the gene FGFR1 and osteoglophonic dysplasia.